Trial Profile
A phase I trial single-ascending dose of SAGE-324 for essential tremor
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Oct 2020
Price :
$35
*
At a glance
- Drugs SAGE-324 (Primary)
- Indications Essential tremor
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 16 Sep 2020 Results presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 01 May 2020 Results (n=11) of single-dose phase 1b assessing safety, tolerability, pharmacokinetics were presented at the 72nd Annual Meeting of the American Academy of Neurology
- 07 Jan 2019 According to a Sage Therapeutics media release, the company recently completed this study. Topline results from this SAD study is expected in 1H 2019.